TATE and Pembrolizumab (MK3475) in mCRC and NSCLC

Description

Patients with refractory metastatic colorectal cancer or non-small cell lung cancer with liver metastasis treated with Trans-arterial Tirapazamine Embolization along with Pembrolizumab.

Conditions

Colorectal Cancer; Lung Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

Patients with refractory metastatic colorectal cancer or non-small cell lung cancer with liver metastasis treated with Trans-arterial Tirapazamine Embolization along with Pembrolizumab.

An Open Label Phase II Study for the Treatment of Liver Metastatic Colorectal Cancer and Non-Small Cell Lung Cancer With a Combination of TATE (Trans-Arterial Tirapazamine Embolization) and Pembrolizumab

TATE and Pembrolizumab (MK3475) in mCRC and NSCLC

Condition
Colorectal Cancer; Lung Cancer
Intervention / Treatment

-

Contacts and Locations

Orange

University of California, Irvine Medical Center, Orange, California, United States, 92868

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Liver metastatic MSS-mCRC or NSCLC without EGFR or AKT mutations
  • * mCRC progressed on at least two lines of standard chemotherapy; or
  • * NSCLC progressed on chemotherapy and an immune checkpoint inhibitor
  • * Measurable disease
  • * ECOG 0-1
  • * At least 4 weeks from prior chemotherapy and free from chemo-related toxicity
  • * Adequate organ function
  • * Prior organ transplantation
  • * Liver metastasis more than 50%
  • * Oxygen saturation less than 92% in room air
  • * Prior autoimmune disorder
  • * CNS metastasis
  • * Major GI bleeding in the last 2 months

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Teclison Ltd.,

Ray Lee, STUDY_DIRECTOR, Teclison Limited

Study Record Dates

2025-12-31